NewBiologix

Get to know NewBiologix's new BD Manager in "5 Questions with David Kelly!" Hear more about his thoughts on advancing gene and cell therapy, goals for fostering impactful collaborations, and vision for the future of innovation at NewBiologix. David brings incredible expertise and a forward-thinking approach as we expand into the U.S. and prepare for an exciting 2025.

2024 Cell and Gene Therapy Milestones | 🧪 Autoimmune Breakthroughs The past year showed a rapidly growing interest in addressing autoimmune diseases through advances in cell therapy. A pivotal study published in the New England Journal of Medicine this year showed that 15 patients who received a CAR-T for their lupus nephritis did not have symptoms relapse after two years of treatment. There are dozens of clinical trials targeting autoimmune diseases such as lupus, type 1 diabetes, myasthenia gravis, and multiple sclerosis, with expectations for the scope of these therapies to expand further. Read ARM’s latest Sector Snapshot here to see all of this year’s milestones: https://lnkd.in/e_SRS38z If you want to see what's in store for the sector in 2025, register to view ARM's State of the Industry Briefing happening on January 13, 2025: https://lnkd.in/gU_sJjg

Cell and gene therapies are set to redefine medicine, offering sophisticated, personalized solutions for complex conditions. However, significant challenges remain in financing, manufacturing, and scaling these technologies for widespread use.   At NewBiologix, we deliver practical solutions to these challenges. Our efficient manufacturing processes and scalable platforms enable biotech and pharma companies to accelerate the delivery of advanced therapies—making them more accessible and cost-effective.   Discover the opportunities and challenges in cell and gene therapies: https://bit.ly/3PeyQUY   #CellTherapy #GeneTherapy #BIOEurope #NewBiologix

Happy Holidays from NewBiologix! Here’s to a joyous holiday season and an exciting year ahead, full of opportunities to advance cell and gene therapies for a better future. Wishing you health, happiness, and success in 2025!

In case you missed it - NewBiologix has officially expanded to the U.S. to better serve its growing customer base. With this new hub, we're enhancing our ability to deliver innovative, scalable solutions for viral vector production in the world's largest biotech market. Learn more about our U.S. expansion and how we’re driving advancements in CGT manufacturing >> https://bit.ly/3P4xfkE #GeneTherapy #CellTherapy #NewBiologix #BiotechInnovation

In a recent Cell & Gene Therapy Review Article, Igor Fisch comments on Switzerland's growing role as a hub for cell and gene therapies. We're honored to be recognized in Switzerland for our contributions to advancing gene and cell therapy development. At NewBiologix, we're focused on improving scalable, cost-effective viral vector production to support the future of these transformative therapies. Learn more about Switzerland's emerging leadership in cell and gene therapies: http://bit.ly/3ZWW883 #CellTherapy #GeneTherapy #BiotechInnovation #NewBiologix

Weekend Read: FDA Approves First Gene Therapy for AADC Deficiency Recently announced by the FDA, this milestone highlights the transformative potential of gene therapy for treating rare genetic diseases while underscoring the ongoing challenges of scaling production, reducing costs and accelerating timelines. At NewBiologix, we’re addressing these barriers with Swiss-engineered innovations to make gene therapy safer, more reliable and scalable. Read the article here >> https://bit.ly/3ZBgLFz #GeneTherapy #FDAApproval #Innovation #CellAndGeneTherapy

📢 Exciting News! We’re thrilled to announce the launch of our U.S. subsidiary, a significant milestone in our mission to transform the production of viral vectors for gene and cell therapy. This expansion strengthens our ability to provide real-time support and collaboration to our growing customer base in the world’s largest biotech market. We also welcome David Kelly, a renowned gene and cell therapy expert, as our new Business Development Manager. His expertise will drive innovation and deepen customer partnerships. Read the full press release >> https://lnkd.in/eHAF493b #GeneTherapy #CellTherapy #NewBiologix #BiotechInnovation

Gene therapies have the potential to transform many lives, but their high costs present a major challenge for accessibility. As Bloomberg Law's latest article discusses, employer coverage is grappling with creative ways to meet this demand. At NewBiologix, we believe affordability begins with innovation. By driving breakthroughs in gene therapy production, we can create a future where life-changing therapies become accessible to all. Read the article here >> https://bit.ly/4gn34kx #GeneTherapy #Innovation #NewBiologix #Biotech

In case you missed it! Learn more about The Xcell™ Portfolio from NewBiologix— a suite of advanced technologies designed to drive production of the next generation of gene and cell therapies. With Swiss precision and unparalleled expertise, Xcell™ delivers a robust foundation for developing and manufacturing reliable, innovative therapies. Explore the future of gene therapy with us! Learn more here >> https://lnkd.in/eDp6ntwn #GeneTherapy #BiotechInnovation #XcellPortfolio